RFC2 and cancer: Consistent with transcriptomic data, RFC2, HSP90AB1, and YWHAZ were significantly elevated in cancer patients (e.g., RFC2: 18.6 ± 2.1 ng/mL in patients vs. 8.2 ± 1.4 ng/mL in controls, p < 0.001).